Диссертация (Токсические фосфорные некрозы лицевого черепа), страница 41
Описание файла
Файл "Диссертация" внутри архива находится в папке "Токсические фосфорные некрозы лицевого черепа". PDF-файл из архива "Токсические фосфорные некрозы лицевого черепа", который расположен в категории "". Всё это находится в предмете "медицина" из Аспирантура и докторантура, которые можно найти в файловом архиве МГМУ им. Сеченова. Не смотря на прямую связь этого архива с МГМУ им. Сеченова, его также можно найти и в других разделах. , а ещё этот архив представляет собой докторскую диссертацию, поэтому ещё представлен в разделе всех диссертаций на соискание учёной степени доктора медицинских наук.
Просмотр PDF-файла онлайн
Текст 41 страницы из PDF
J Oral Surg 1977;35:989–991.[PubMed: 336855]293. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of thejaw caused by soft tissue toxicity? Bone 2007;41(3):318-20.294. Reiriz A.B., Zorzi P.M., Lovat C.P. Bisphosphonates and osteonecrosis of thejaw: a case report // CLINICS 2008;63(2):281-4295. Resnick D, Niwayama G. Diagnosis of bone and joint disorders. 1st ed.Philadelphia: WB-Saunders, 1981:2045.296. Reuther T, Schuster T, Mende U, Kubler A: Osteoradionecrosis of the jaws as aside effect of radiotherapy of head and neck tumour patients a report of a thirty yearretrospective review. Int J Oral Maxillofac Surg 2003, 32:289-295.297.
Rizzoli R., Burlet N., Cahall D., Delmas P.D., Eriksen E.F., Felsenberg D., GrbicJ., Jontell M., Landesberg R., Laslop A., Matton P., Papapoulos S., Sezer O., SprafkaM.,ReginsterJ.Y.ОСТЕОНЕКРОЗЧЕЛЮСТИУПАЦИЕНТОВСОСТЕОПОРОЗОМ // Остеопороз и остеопатии. 2007. Т. 2. № 2. С. 19-21.298. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action.
J Clin Invest1996;97(12):2692-6.299. Rogers MJ, Frith JC, Luckman P, et al. Molecular mechanisms of action ofbisphosphonates. Bone. 1999;24(suppl):73S-79S.300. Rogers MJ, Watts DJ, Russell RG. Overview of bisphosphonates. Cancer1997;80(supplement 8):1652-60.301. Roodman GD: Pathogenesis of myeloma bone disease. Blood Cells Mol Dis32:290-292, 2004302. Rosenthall, L., and Kaye, M.: Technetium-99m-Pyrophosphate Kinetics andImaging in Metabolic Bone Disease, J. Nucl.
Med. 16: 33-39, 1975.303. Ruggiero S.L., Dodson T.B., Assael L.A., Landesberg R., Marx R.E., MehrotraB. American Association of Oral and Maxillofacial Surgeons position paper onbisphosphonate-related osteonecrosis of the jaw - 2009 update // Aust Endod J. 2009Dec;35(3):119-30.327304. Ruggiero S.L., Drew S.J. Osteonecrosis of the Jaws and Bisphosphonate Therapy// J Dent Res 86(11):1013-1021, 2007305. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B,O’Ryan F, American Association of Oral and Maxillofacial Surgeons Position Paper onMedication-Related Osteonecrosis of the Jaw—2014 Update, Journal of Oral andMaxillofacial Surgery (2014), doi: 10.1016/j.joms.2014.04.031.306. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of thejaw: background and guidelines for diagnosis, staging and management.
Oral Surg OralPathol Oral Med 2006;102:433–4307. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jawsassociated with the use of bisphosphonates: a review of 63 cases. J Oral MaxillofacSurg. 2004;62:527-34. [PMID: 15122554]308. Russell RG, Rogers MJ, Frith JC, et al. The pharmacology of bisphosphonatesand new insights into theirmechanisms of action.J Bone Miner Res1999;14(supplement 2):53-65.309.
Russell RGG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic andback again. Bone 1999;25:97–106.310. Sanna G, Zampino MG, Pelosi G, Nole F, Goldhirsh A 2005 Jaw avascular bonenecrosis associated with long-term use of bisphosphonates. Ann Oncol 16:1207–1208.311. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, SalernoA, Denaro V, Tonini G: Pamidronate induces modifications of circulating angiogeneticfactors in cancer patients.
Clin Cancer Res 2002, 8:1080-1084.312. Sarathy AP, Bourgeois SL Jr, Goodell GG. Bisphosphonate-associatedosteonecrosis of the jaws and endodontic treatment: two case reports. J Endod.2005;31:759-63. [PMID: 16186759]313. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E,Rodan GA: Bisphosphonate action — alendronate localization in rat bone and effects onosteoclast ultrastructure. J Clin Invest 1991, 88:2095-2105.314.
Schenk R, Merz WA, Muhlbauer RC, Russell RGG, Fleisch H: Effect of ethane1-hydroxy-1,1-diphosphonate(EHDP)anddichlorormethylenediphosphonate328(Cl2MDP) on the calcification and resorption of cartilage and bone in the tibialepiphysis and metaphysis of rats. Calcif Tissue Res 1973, 11:196-214.315. Scully C.
Oral ulceration: a new and unusual complication. Br Dent J2002;192(3):139-140.316. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonatesinduce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459-68.317. Shafer WG, Hine MK, Levy BM. A textbook of oral pathology. 4th ed.Philadelphia: WB Saunders, 1983:506-8.318. SHAFER, W. G.: Chronic sclerosing osteomyelitis. Oral Surg. 1957: 15: 138142.319. Shannon MT, Sclaroff A, Colm SJ.
Invasive aspergillosis of the maxilla in animmunocompromisedpatient. Oral Surg Oral Med Oral Pathol 1990;70:425–427.[PubMed: 2120652]320. Shipman CM, Croucher PI, Russell RGG, Helfrich MH, RogersMJ: Thebisphosphonate incadronate (ym175) causes apoptosis of human myeloma cells in vitroby inhibiting the mevalonate pathway. Cancer Res 1998, 58:5294-5297.321. Shipman CM, Rogers MJ, Apperley JF, Graham R, Russell G, Croucher PI:Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumouractivity. Br J Haematol 1997, 98:665-672.322. Sietsema WK, Ebetino FH, Salvagno AM, Bevan JA. Antiresorptive dosedependent relationship across three generations of bisphosphonates.
Drugs Exp Clin Res1989;15:389-96.323. Sitters MA, Caldwell CS. Bisphosphonates, dental care and osteonecrosis of thejaws. Tex Dent J. 2005;122:968-72. [PMID: 16320504]324. Skikevich M.G., Avetikov D.S. TOXIC OSTEOMYELITIS OF THE JAWONES AGAINST THE BACKGROUNDS OF CHRONIC INTOXICATION // Свiтмедицини та бiологii. 2013. Т.
9. № 1 (36). С. 194-196.325. Sonnier KE, Horning GM. Spontaneous bony exposure: a report of 4 cases ofidiopathic exposure and sequestration of alveolar bone. J Periodontol 1997;68(8):758762.329326. Soubrier M, Dubost JJ, Ristori JM, et al: Pamidronate in the tx of diffusesclerosing osteomyelitis of the mandible. Oral Surg Oral Med Oral Pathol Oral RadiolEndod 92:637, 2001327. Sparidans RW, Twiss IM, Talbot S.
Bisphosphonates in bone diseases. PharmWorld Sci 1998;20:206-213.328. Starck WJ, Epker BN. Failure of osseointegrated dental implants afterdiphosphonate therapy for osteoporosis: a case report. Int J Oral MaxillofacImplants.1995;10:74-8. [PMID: 7615320]329. Stockman R. 0n the cause of so-called phosphorus necrosis of the jaw inmatchworkers // The British Medical Journal – Jan.7, 1899.- P. 9-10330. Suei Y, Tanimoto K, Miyauchi M, et al: Partial resection of the mandible for thetreatment of diffuse sclerosing osteomyelitis: Report of four cases.
J Oral MaxillofacSurg 55:410, 1997331. Thoma, K. H., and Goldman, H. M.: Oral pathology, ed. 5, St. Louis, 1960, TheC. V. Mosby Company, pp. 677-780.332. Throndson RR, Healy SM, Zwickey MR. Bisphosphonate-induced osteonecrosisof the jaws. Tex Dent J. 2005;122:960-5. [PMID: 16320503]333. Tian E, Zhan F, Walker R, et al: The role of the Wnt-signaling antagonist DKK1in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:24832494, 2003334. Tosi P, Zamagni E, Cangini D, et al. Bisphosphonates and osteonecrosis of thejaws: incidence in a homogeneous series of patients with newly diagnosed multiplemyeloma treated with zoledronic acid.
Blood. (American Society of HematologyAnnual Meeting Abstracts) 106:3461, 2005335. Tosi P, Zamagni E, Cangini D, Tachetti P, DiRaimondo F, Catalano L, DÁrco A,Ronconi S, Cellini C, Offidani M, Perrone G, Ceccolinin M, Brioli A, Tura S, BaccaraniM, Cavo M 2006 Osteonecrosis of the jaws in newly diagnosed multiple myelomapatients treated with zoledronic acid and thalidomide-dexamethasone. Blood 108:3951–3952.330336. TURLINGTON, E. G.: Chronic sclerosing nonsuppurative osteomyelitis.
In:KAY, L. W. (ed.): Oral surgery. Munksgaard, Copenhagen 1973, pp. 120-124.337. Turner J.H. Treatment of painful skeletal metastases. Alasbimn Journal, SpecialIssue: 8-th World Congress of Nuclear Medicine, n17, sept. 2002.338. Uluibau IC, Jaunay T, Goss AN. Severe odontogenic infections. Aust Dent J2005;50 Suppl 2:S74-S81.339. United States Food and Drug Administration.
Center for Drug Evaluation andResearch.Availableathttp://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed November 11, 2008.340. van Merkesteyn JPR, Groot RH, Bras J, McCarroll RS, Bakker DJ. Diffusesclerosing osteomyelitis of the mandible: a new concept of its etiology. ORAL SURGORAL MED ORAL PATHOL 1990;70:414-9.341. Vannucchi AM, Ficarra G, Antonioli E, Bosi A. Osteonecrosis of the jawassociated with zoledronate therapy in a patient with multiple myeloma.
